Is Egrifta (Tesamorelin) Legal in Michigan? How to Access It Legally

Federal Legal Status: The Foundation You Must Understand First

Tesamorelin is an FDA-approved drug, not a gray-area research chemical. The FDA granted approval in 2010 under the brand name Egrifta, and an updated formulation, Egrifta SV (2 mg/vial), received approval in 2019. [1][2] Because the drug has an approved New Drug Application (NDA), the federal Controlled Substances Act (CSA) does not schedule it, and the Drug Enforcement Administration (DEA) does not regulate its possession or distribution. [3]

That approval status matters enormously for Michigan residents. A drug with an active NDA can be prescribed, dispensed by any licensed pharmacy, and shipped across state lines in finished, commercially manufactured form without any special state exemption.

What the FDA Approval Actually Covers

The approved indication is narrow: "treatment of excess abdominal fat in HIV-infected patients with lipodystrophy." [1] The FDA's clinical basis for that indication rests on two randomized, placebo-controlled phase-3 trials. In the key LIPO study (N=412), tesamorelin 2 mg once daily reduced visceral adipose tissue (VAT) by a mean of 18% versus a 5% increase in the placebo arm at 26 weeks (P<0.001). [4] A second trial (N=391) confirmed maintenance of VAT reduction over 52 weeks. [5]

Prescribers in Michigan may legally prescribe Egrifta SV off-label for other indications, because off-label prescribing of FDA-approved drugs is lawful under both federal law and Michigan's Public Health Code (MCL 333.7333). [6] However, the legal status of compounding tesamorelin for off-label use is a separate and more complex question addressed below.

Growth Hormone-Releasing Hormone (GHRH) Classification

Tesamorelin is a synthetic analogue of endogenous GHRH (also called growth hormone-releasing factor, GHRF). [7] It is not human growth hormone (hGH) itself. That distinction is legally significant: hGH is a controlled substance under 21 U.S.C. 333(e), and federal law restricts its use to FDA-approved indications. Tesamorelin carries no equivalent restriction. [3][8]

Michigan State Law: What the Michigan Public Health Code Says

Michigan does not have a separate state-level law that schedules tesamorelin or restricts its prescription beyond standard Michigan prescribing requirements. The Michigan Controlled Substances Act (Michigan Public Health Code, Part 72) mirrors the federal CSA schedules and adds a small number of Michigan-specific substances. Tesamorelin does not appear on either list. [9]

Michigan Prescribing Requirements

Any Michigan-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) with full prescriptive authority may write a prescription for Egrifta SV under MCL 333.17745 and MCL 333.17211. [6][10] The prescription must include the standard Michigan elements: patient name, date, drug name and strength, quantity, directions, and prescriber DEA number (even though tesamorelin is not a controlled substance, most pharmacy software requires it for verification). Prescriptions may be transmitted electronically, by fax, or in writing.

Michigan Board of Pharmacy Oversight

The Michigan Board of Pharmacy licenses and inspects all in-state pharmacies under MCL 333.17731. [10] A Michigan retail pharmacy may dispense commercially manufactured Egrifta SV against a valid prescription without any special compounding permit. If a pharmacy compounds tesamorelin instead of dispensing the commercial product, additional federal and state requirements apply, as outlined in the next section.

Compounded Tesamorelin in Michigan: 503A and 503B Rules

Compounded tesamorelin exists in a legal gray area that is narrower than many online sources suggest. The FDA Modernization Act of 1997 and its 2013 update (Drug Quality and Security Act, DQSA) established two compounding frameworks. Both apply in Michigan because the state has adopted policies consistent with federal compounding guidance. [11]

503A Retail Compounding Pharmacies

A 503A pharmacy may compound tesamorelin for an individual patient if all of the following conditions are met simultaneously. [11][12]

• A licensed prescriber has issued a valid patient-specific prescription.
• The compounded preparation is not essentially a copy of a commercially available drug.
• The drug substance (tesamorelin acetate) is on the FDA's list of bulk substances that may be used in compounding, or qualifies under a category-1 nomination pending review.
• The pharmacy does not compound the preparation in inordinate amounts.

The "not essentially a copy" requirement creates the primary legal tension. Egrifta SV is commercially available; a 503A pharmacy compounding tesamorelin at 2 mg/vial in the same formulation could be considered an essentially equivalent copy, which is prohibited. [12] Some 503A pharmacies argue that alternative concentrations, routes, or formulations (such as a subcutaneous pen cartridge versus a lyophilized vial) avoid the copy restriction. The FDA has not issued definitive guidance on this specific scenario as of the date this article was reviewed.

A Michigan patient who obtains compounded tesamorelin from a 503A pharmacy operating within these rules is not violating any law. The pharmacy bears the legal compliance burden, not the patient. [11]

503B Outsourcing Facilities

A 503B outsourcing facility may compound tesamorelin without a patient-specific prescription and may sell to hospitals and clinics, but only if tesamorelin appears on the FDA's 503B Bulks List. [13] As of January 2025, tesamorelin is not on the 503B Bulks List; the FDA's current 503B list can be verified at the FDA's official outsourcing facility page. [13] This means no Michigan clinic may legally obtain bulk-compounded tesamorelin from a 503B facility for office dispensing or stocking purposes.

The FDA's Bulk Drug Substance Nomination Process

Tesamorelin has been nominated for inclusion on the 503A bulk substances list by compounding pharmacies. The FDA categorizes nominated substances as Category 1 (under review), Category 2 (clinical need not demonstrated), or Category 3 (insufficient information). [14] Michigan prescribers and patients should verify the current category before ordering any compounded preparation. The FDA's active nomination list is maintained at the agency's compounding page. [14]

How to Get a Legal Egrifta (Tesamorelin) Prescription in Michigan

Step 1: Confirm You Meet the FDA-Approved Indication

Egrifta SV is FDA-approved only for HIV-positive adults with lipodystrophy-associated excess visceral fat. Meeting this criterion is the straightforward path to commercial-product coverage and the clearest legal route. [1] A 2020 clinical review published in the Journal of the Endocrine Society confirmed that tesamorelin produces statistically significant reductions in VAT (mean reduction 18.6 cm² by CT scan) with a favorable safety profile in this population. [15]

Step 2: See a Michigan-Licensed Prescriber

Schedule a consultation with a Michigan-licensed physician, NP, or PA. At HealthRX, consultations are conducted by board-certified providers licensed in Michigan. The prescriber will review your HIV status, current antiretroviral therapy, body composition data, metabolic labs, and contraindications (active malignancy, pregnancy, pituitary disease, and hypersensitivity to tesamorelin or mannitol are all listed in the Egrifta SV prescribing information). [1]

Baseline fasting glucose and HbA1c are standard before initiating therapy, because tesamorelin raises IGF-1 and may impair glucose tolerance in some patients. [1][16] In the phase-3 trials, new-onset diabetes occurred in 4.3% of tesamorelin-treated patients versus 2.2% of placebo patients at 26 weeks. [4]

Step 3: Obtain the Prescription at a Michigan-Licensed Pharmacy

Egrifta SV is distributed through specialty pharmacy networks. Theratechnologies, the manufacturer, operates a patient support program called the EGRIFTAssist program that helps with prior authorization and, for eligible patients, copay assistance. [17] The drug's list price is high (exceeding $3,000 per month without insurance), so insurance verification is an essential part of the dispensing process.

Michigan Medicaid covers Egrifta SV for HIV-associated lipodystrophy with prior authorization under the Healthy Michigan Plan. [18] Commercial plans vary; your prescriber's office should submit documentation of HIV status and VAT measurements to support the prior-authorization request.

Step 4: Proper Storage and Administration

Egrifta SV lyophilized powder must be refrigerated at 2°C to 8°C before reconstitution. [1] After mixing with the supplied diluent, the solution is stable for up to 24 hours in the refrigerator. Each dose is 2 mg injected subcutaneously into the abdomen, avoiding the umbilical region, once daily. Michigan law does not restrict self-injection of prescribed non-controlled peptides in the home setting.

Off-Label Tesamorelin Use in Michigan: What the Evidence Shows

Prescribers sometimes consider tesamorelin for non-HIV patients with visceral obesity, age-related GH decline, or cognitive outcomes research. Off-label prescribing is legal in Michigan. The clinical evidence, however, remains at an early stage for these applications.

Visceral Obesity Without HIV

A 2016 randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=155, non-HIV adults with abdominal obesity) found that tesamorelin 2 mg daily for 52 weeks reduced VAT by 18.7% compared with a 1.5% increase in placebo (P<0.001). [19] The authors noted that VAT returned to near-baseline levels within 12 weeks of stopping treatment, suggesting the effect is not durable without ongoing use.

Cognitive Function and Alzheimer's Disease Risk

A 2021 trial published in Nature Communications (N=152) examined tesamorelin's effect on cognition in older adults with mild cognitive impairment. After 20 months, the tesamorelin group showed significantly less decline on the Modified Alzheimer's Disease Assessment Scale-Cognitive Subscale compared with placebo (P<0.05). [20] This remains investigational and is not an FDA-approved use.

Non-Alcoholic Fatty Liver Disease (NAFLD)

A small pilot study (N=31) published in Clinical Gastroenterology and Hepatology found that tesamorelin reduced liver fat by approximately 32% versus 8% in placebo over 12 months in HIV-infected adults with NAFLD. [21] Larger trials are ongoing. Off-label prescribing for NAFLD in Michigan is legal but not supported by an approved indication.

Key Legal Boundaries: What Is NOT Permitted in Michigan

Understanding what the law prohibits protects patients from legal risk and ensures they receive genuine, quality-assured medication.

Purchasing Tesamorelin Without a Prescription

Tesamorelin sold on websites as a "research chemical" or "for laboratory use only" exists outside FDA oversight. Purchasing such products for human use violates the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 301. [22] Michigan's Public Health Code imposes additional penalties for obtaining prescription drugs without a valid prescription under MCL 333.7403. [9] The FDA has issued multiple warning letters to companies selling unapproved peptides in this category. [22]

Importing Tesamorelin From Foreign Sources

Personal importation of unapproved prescription drugs through international channels violates FDA import regulations. The FDA's personal importation policy does not protect purchases of drugs that have an FDA-approved domestic equivalent. [23] Egrifta SV has a domestic-approved equivalent, so no personal importation exemption applies.

Compounded Tesamorelin From Non-Registered Facilities

Only pharmacies registered with the state of Michigan and, where applicable, with the FDA as outsourcing facilities may legally compound prescription drugs for Michigan patients. Using a non-registered online "pharmacy" that ships compounded tesamorelin without a patient-specific prescription violates both federal law and Michigan's Pharmacy Practice Act. [11][24]

Monitoring and Safety: What Michigan Prescribers Require

Tesamorelin is generally well-tolerated but requires structured follow-up. The FDA-approved prescribing information specifies that IGF-1 levels should be measured at baseline and periodically during treatment; dose reduction is recommended if IGF-1 exceeds the upper limit of normal. [1]

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency states: "We suggest against the use of GH secretagogues or GHRH analogues outside of an approved indication or a registered clinical trial in the absence of strong safety data in non-HIV populations." [25] Michigan prescribers operating within the HealthRX platform follow this guidance and require documented clinical justification for any off-label use.

Routine monitoring typically includes fasting glucose and HbA1c every 3 months, IGF-1 every 3 to 6 months, and a repeat body composition assessment (DEXA or waist circumference) at 26 weeks. [1][15] Patients with pre-diabetes should be counseled about the modest increased risk of glucose impairment before starting therapy.

Summary of Legal Pathways: A Decision Framework for Michigan Patients

The following framework organizes the legal access options from most to least straightforward.

Pathway 1 (clearest legal standing): HIV-positive Michigan adult with documented lipodystrophy, prescription from a Michigan-licensed provider, commercially manufactured Egrifta SV dispensed by a Michigan-licensed specialty pharmacy. This pathway involves no legal ambiguity at any step.

Pathway 2 (legally permissible with conditions): Non-HIV Michigan adult, off-label prescription from a Michigan-licensed provider, compounded tesamorelin from a 503A-compliant Michigan pharmacy that can document the compounded preparation is not an essentially equivalent copy of Egrifta SV and that the bulk substance meets current FDA 503A requirements. Legal compliance depends entirely on the pharmacy's adherence to federal compounding standards.

Pathway 3 (not legally permissible): Any Michigan resident purchasing tesamorelin online without a prescription, importing from foreign pharmacies, or obtaining from non-registered compounders. This pathway violates federal and Michigan law regardless of the intended use.